Calidi Biotherapeutics
CLDI
20 hedge funds and large institutions have $36.1M invested in Calidi Biotherapeutics in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 0 increasing their positions, 7 reducing their positions, and 30 closing their positions.
0.04% less ownership
Funds ownership: 0.05% → 0.01% (-0.04%)
51% less funds holding
Funds holding: 41 → 20 (-21)
70% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 30
82% less capital invested
Capital invested by funds: $206M → $36.1M (-$169M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$3.99M |
| 2 |
LSC
Logan Stone Capital
Chicago,
Illinois
|
+$1.5M |
| 3 |
SFM
Spartan Fund Management
Toronto, Ontario,
Canada
|
+$1.5M |
| 4 |
KL
KIM LLC
Wichita,
Kansas
|
+$997K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$940K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$18.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$15.8M |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$12M |
| 4 |
AMH
Apollo Management Holdings
New York
|
-$11.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$10.6M |
CLDI Hedge Fund Activity: Q3 2022 in Review
20 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q3 2022, worth a combined $36.1M — down 82% from $206M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of CLDI and 9 opened new positions — a net loss of 21 holders — while 7 trimmed existing stakes and 0 added.
The largest buyer was First Trust Capital Management, opening a new position worth an estimated $3.99M. The largest seller was Polar Asset Management Partners, cutting an estimated $18.2M.
- 20 institutional investors held Calidi Biotherapeutics (CLDI) as of Q3 2022, down from 41 in Q2 2022.
- Funds reported $36.1M of Calidi Biotherapeutics stock for Q3 2022, down 82% quarter-over-quarter.
- 9 funds opened new Calidi Biotherapeutics positions in Q3 2022 and 30 closed out, a net change of -21 holders.
- The largest Calidi Biotherapeutics buyer in Q3 2022 was First Trust Capital Management, an estimated $3.99M added.
- The largest Calidi Biotherapeutics seller in Q3 2022 was Polar Asset Management Partners, an estimated $18.2M sold.
Based on aggregated 13F filings for Q3 2022.